PDCD1 and neoplasm: reported that macitane inhibits the secretion of tumor-derived EV-PD-L1 in breast cancer cells by targeting endothelin receptor A (ETA) and can reduce the binding of PD-1 to EV-PD-L1, thereby synergizing the effect of anti-PD-L1 antibodies.